-
公开(公告)号：JP6970105B2
公开(公告)日：2021-11-24
申请号：JP2018541655
申请日：2017-02-09
Applicant: スティヒティング カソリーケ ユニベルシタイト , STICHTING KATHOLIEKE UNIVERSITEIT
Inventor： シリス トム ヨハン ヨセフ , リッチェル ティナ , ルティエス フローリス ペトルス ヨハネス テオドロス , スメイティンク ヨハネス アルベルトゥス マリア , ラッセル フランソワ ジェラルド マリー
IPC: A61P43/00 , A61P9/00 , A61P3/06 , A61P3/00 , A61P13/12 , A61P25/28 , A61P29/00 , C07D403/06 , C07D413/06 , C07D271/07 , A61K31/505 , A61K31/506 , A61K31/4245 , A61K31/41 , A61K31/405 , A61K31/40 , C07D257/04
-
公开(公告)号：JP2020509741A
公开(公告)日：2020-04-02
申请号：JP2019547096
申请日：2018-03-07
Applicant: スティッチング カソリーケ ウニベルシテイト , STICHTING KATHOLIEKE UNIVERSITEIT
Inventor： リーンダーズ, ウィルヘルムス ペトルス ヨハネス
IPC: C12Q1/6869 , C12N15/12 , C12Q1/06 , C12Q1/6883 , A61K45/00 , A61P35/00 , A61P31/12 , A61P31/04 , A61P35/02 , A61P37/06 , A61P43/00 , G01N33/50 , C12Q1/6827
Abstract: 本発明は、医療及び分子診断法の分野に関する。特に、本発明は、代謝に関与する遺伝子を含む疾患に関与する遺伝子からの、転写産物及びその選択的スプライスバリアント並びにその中の変異の同時検出を可能にし、食品化合物、栄養補助食品又は代謝の阻害剤と組み合わせた、疾患関連分子異常を標的にする薬物による個別化治療のアドバイスをもたらす、新規のRNA次世代シーケンシングベースのプロファイリングアッセイに関する。 【選択図】なし
-
公开(公告)号：JP4944041B2
公开(公告)日：2012-05-30
申请号：JP2007547391
申请日：2005-12-23
Inventor： ヴィトイェス，アルフレット，イェー． , スハールケン，ヤック，アー． , フェルハーフ，ヘラルト , ヘッセルス，ダフネ
IPC: C12N15/09 , C12Q1/68 , G01N33/574
CPC classification number: C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158 , C12Q2600/16 , G01N33/57434 , G01N2333/96455
Abstract: Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
-
公开(公告)号：TWI389694B
公开(公告)日：2013-03-21
申请号：TW098144222
申请日：2009-12-22
Applicant: 英特威特國際股份有限公司 , INTERVET INTERNATIONAL B. V. , 史迪汀荷蘭語大學 , STICHTING KATHOLIEKE UNIVERSITEIT
Inventor： 史基瑞爾 卡拉 , SCHRIER, CARLA CHRISTINA , 尼爾肯斯 史蒂芬 , NIERKENS, STEFAN , 阿戴瑪 高絲 , ADEMA, GOSSE , 布洛克 丹馬汀 , BROK, DEN MARTIJN , 魯爾斯 里歐朵兒 , RUERS, THEODOOR JAQUES MARIE
IPC: A61K31/704 , A61K31/7088 , A61P35/00
CPC classification number: A61K39/0011 , A61K31/704 , A61K39/39 , A61K2039/5152 , A61K2039/55505 , A61K2039/55561 , A61K2039/55566 , A61K2039/55577
-
公开(公告)号：WO2013006059A1
公开(公告)日：2013-01-10
申请号：PCT/NL2012/050482
申请日：2012-07-05
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT , STICHTING KATHOLIEKE UNIVERSITEIT , PRUIJN, Gerardus Jozef Maria , PLUK, Wilhelmina Lamberta Leonarda Petronell , VAN ENGELEN, Basilius Gerardus Maria
Inventor： PRUIJN, Gerardus Jozef Maria , PLUK, Wilhelmina Lamberta Leonarda Petronell , VAN ENGELEN, Basilius Gerardus Maria
IPC: G01N33/564
CPC classification number: G01N33/573 , G01N33/564 , G01N2333/916 , G01N2800/10 , G01N2800/50 , G01N2800/52 , G01N2800/56
Abstract: The current invention relates to a method for identifying a subject at risk of developing an idiopathic inflammatory myopathy and/or diagnosing a subject suffering from an idiopathic inflammatory myopathy, preferably wherein said idiopathic inflammatory myopathy is Inclusion Body Myositis. The invention provides methods in diagnosis, use of specific antigens, and kits for use in studying the presence or absence of (auto)antibodies in samples derived from subjects.
Abstract translation: 本发明涉及用于鉴定患有特发性炎症性肌病和/或诊断患有特发性炎症性肌病的受试者的风险的受试者的方法，优选其中所述特发性炎性肌病是包涵体肌炎。 本发明提供诊断，使用特异性抗原的方法和用于研究衍生自受试者的样品中（自动）抗体的存在或不存在的试剂盒。
-
Patent Agency Ranking16.发明申请PANTOTHENIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF MICROBIAL INFECTIONS 审中-公开泛酸衍生物及其在治疗微生物感染中的应用
公开(公告)号：WO2011152720A1
公开(公告)日：2011-12-08
申请号：PCT/NL2011/050384
申请日：2011-05-31
Applicant: UMC ST. RADBOUD , STICHTING KATHOLIEKE UNIVERSITEIT, RADBOUD UNIVERSITY NIJMEGEN , STICHTING KATHOLIEKE UNIVERSITEIT, RADBOUD UNIVERSITY NIJMEGEN , ZEEUWEN, Patrick Laurentius Johannes Maria , JANSEN, Patrick Antonius Martinus , SCHALKWIJK, Josephus , RUTJES, Floris Petrus Johannes Theodorus , RITZEN, Bas , HERMKENS, Pedro Harold Han
Inventor： ZEEUWEN, Patrick Laurentius Johannes Maria , JANSEN, Patrick Antonius Martinus , SCHALKWIJK, Josephus , RUTJES, Floris Petrus Johannes Theodorus , RITZEN, Bas , HERMKENS, Pedro Harold Han
IPC: A61K31/16 , A61K31/164 , A61K31/275 , A61K31/277 , A61K31/4155 , A61K31/417 , A61K31/4174 , A61K31/4178
CPC classification number: A61K45/06 , A61K31/16 , A61K31/164 , A61K31/165 , A61K31/275 , A61K31/277 , A61K31/4155 , A61K31/417 , A61K31/4174 , A61K31/4178 , Y02A50/411 , A61K2300/00
Abstract: The present invention concerns novel amides derived from pantothenic acid having antibiotic activity and novel analogues of pantetheine inhibiting the activity of pantetheinase. Combinations of such substances can suitably beused in therapeutic and or prophylactic treatment of bacterial infections, fungal and yeast infections in a human or animal subject. The present invention resides in the findingthat pantothenamidesaloneare not at antibiotically active in the presence of plasma due to the breakdown of pantothenamides by enzymes with pantetheinase activityandthat inhibition of these enzymes prevented breakdown of pantothenamides,thuspreserving their antibiotic activity under physiological conditions in mammals. The present invention thus, for the first time, makes available treatment relying on interference with microbial CoA dependent pathways and, simultaneously, inhibiting or reducing pantetheinase activity.
Abstract translation: 本发明涉及衍生自具有抗生素活性的泛酸的新型酰胺，以及泛酸胺基的新类似物抑制泛肽酶的活性。 这些物质的组合可以适当地用于人或动物受试者的细菌感染，真菌和酵母菌感染的治疗和/或预防性治疗。 本发明在于由于泛酸酰胺酶活性降低泛酸酰胺的作用而在血浆存在下不具有抗生素活性，因此这些酶的抑制可防止泛酰胺的分解，从而在哺乳动物的生理条件下保护其抗生素活性。 因此，本发明首次能够依赖于干扰微生物CoA依赖途径的治疗，同时抑制或减少泛酰胺氨基酸酶活性。
-
17.发明申请
公开(公告)号：WO2011152721A1
公开(公告)日：2011-12-08
申请号：PCT/NL2011/050385
申请日：2011-05-31
Applicant: UMC ST. RADBOUD , STICHTING KATHOLIEKE UNIVERSITEIT, RADBOUD UNIVERSITY NIJMEGEN , STICHTING KATHOLIEKE UNIVERSITEIT, RADBOUD , JANSEN, Patrick Antonius Martinus , SCHALKWIJK, Josephus , RUTJES, Floris Petrus Johannes Theodorus , SAUERWEIN, Robert , HERMKENS, Pedro Harold Han
Inventor： JANSEN, Patrick Antonius Martinus , SCHALKWIJK, Josephus , RUTJES, Floris Petrus Johannes Theodorus , SAUERWEIN, Robert , HERMKENS, Pedro Harold Han
IPC: A61K31/16 , A61K31/164 , A61K31/165 , A61K31/275 , A61K31/417 , A61K31/4174 , A61K31/4178 , A61K31/4155 , A61K31/277 , A61K45/06 , A61P33/06
CPC classification number: A61K45/06 , A61K31/16 , A61K31/164 , A61K31/165 , A61K31/275 , A61K31/277 , A61K31/4155 , A61K31/417 , A61K31/4174 , A61K31/4178 , Y02A50/411 , A61K2300/00
Abstract: The present invention concerns novel pantothenone compounds having pantetheinase inhibitory activity as well as antiplasmodial activity. These compounds can suitably be used in therapeutic and or prophylactic treatment of malaria. Furthermore, the present invention provides combinations of pantothenone compounds and pantothenamides. Combining a pantothenone with a pantothenamide increases the antimalarial potency by an order of magnitude. It is hypothesized that inhibition of pantetheinase activity could protect pantothenamides against degradation by serum-derived pantetheinases, thereby revealing the hitherto unknown antimalaria activity of pantothenamides. The present invention thus, for the first time, makes available compounds and combinations of compounds for use in therapeutic and or prophylactic treatment of malaria infection in a human or animal subject in need thereof, relying on interference with host or pathogen-derived pantetheinase dependent pathways.
Abstract translation: 本发明涉及具有泛肽酶抑制活性以及抗血浆活性的新型泛氢化合物。 这些化合物可适用于治疗和/或预防性治疗疟疾。 此外，本发明提供了泛醌化合物和泛酸酰胺的组合。 将泛氢化合物与泛酸盐组合使抗疟药效力提高一个数量级。 假设抑制泛酰胺酶活性可以保护泛酸酰胺免受血清衍生的泛酰胺氨基酸酶的降解，从而揭示迄今未知的泛酰胺的抗疟疾活性。 因此，本发明首次使得可用的化合物和化合物的组合用于治疗和/或预防性治疗有需要的人或动物受试者中的疟疾感染，依赖于干扰宿主或病原体衍生的泛酰胺氨基酸酶依赖途径 。
-
18.发明申请
公开(公告)号：WO2012004369A1
公开(公告)日：2012-01-12
申请号：PCT/EP2011/061559
申请日：2011-07-07
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT, MEER IN HET BIJZONDER RADBOUD UNIVERSITEIT NIJMEGEN , STICHTING KATHOLIEKE UNIVERSITEIT , ROWAN, Alan Edward , FIGDOR, Carl Gustav
Inventor： ROWAN, Alan Edward , FIGDOR, Carl Gustav
CPC classification number: A61K47/48192 , A61K47/59 , A61K47/60 , A61K47/646
Abstract: The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example for immunotherapy such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and/or diagnostic purposes.
Abstract translation: 本发明涉及包含一个或多个肽，蛋白质，因子，化合物或本文进一步描述的其它组分的蛋白质构建体，其通过螺旋聚合物主链相互连接和/或彼此连接。 本发明的构建体适用于给予人或动物体并且可用于药物目的，例如用于免疫治疗，例如用于治疗癌症和其它免疫应用，以及其它治疗，预防和/或诊断 目的。
-
公开(公告)号：AU2009331531B2
公开(公告)日：2013-06-13
申请号：AU2009331531
申请日：2009-12-22
Applicant: INTERVET INT BV , STICHTING KATHOLIEKE UNIVERSITEIT UNIVERSITAIR MEDISCH CENRUM ST RADBOUD
Inventor： SCHRIER CARLA CHRISTINA , NIERKENS STEFAN , ADEMA GOSSE , BROK DEN MARTIJN , RUERS THEODOOR JAQUES MARIE
IPC: A61K31/704 , A61K31/7088 , A61K39/39 , A61P35/00
Abstract: The present invention relates to pharmaceutical compositions for use in
-
公开(公告)号：NL2007179C2
公开(公告)日：2013-01-29
申请号：NL2007179
申请日：2011-07-26
Applicant: STICHTING KATHOLIEKE UNIVERSITEIT
-
-
-
-
-
-
-
-
-
Search Results
452
records
(took 0.033 seconds)
